Refine Search

Search Results -

Terms	Documents
succinimide.ti.	1255

Database: US Pre-Grant Publication Full-Text Database; US Patents Full-Text Database; US OCR Full-Text Database; EPO Abstracts Database; JPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L8 and (cancer or prostate)

Refine Search | Recall Text | Clear | Interrupt

Search History

DATE: Tuesday, December 30, 2003 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=AND			
L8	succinimide.ti.	1255	L8
L7	succinimide near fused	1	L7
L6	succinimide near fused	1	L6
L5	succinimide	19480	L5
DB=USPT; PLUR=YES; OP=AND			
L4	L3 and (cancer or prostate)	96	L4
L3	l1 and succinimide	386	L3
L2	L1 and prostate adj cancer	164	L2
L1	(514/408-448)![CCLS]	9275	L1

END OF SEARCH HISTORY

```
=> d hist

     (FILE 'HOME' ENTERED AT 10:13:09 ON 30 DEC 2003)

     FILE 'REGISTRY' ENTERED AT 10:13:15 ON 30 DEC 2003
L1                STRUCTURE UPLOADED
L2              0 S SAM L1
L3                STRUCTURE UPLOADED
L4             29 S SAM L3
L5           2157 S FULL L3

     FILE 'CAPLUS' ENTERED AT 10:18:33 ON 30 DEC 2003
L6            617 S L5
L7              3 S L6 AND CANCER

     FILE 'REGISTRY' ENTERED AT 10:22:32 ON 30 DEC 2003
L8                STRUCTURE UPLOADED
L9             50 S SAM L8
L10          6697 S FULL L8

     FILE 'CAPLUS' ENTERED AT 10:24:20 ON 30 DEC 2003
L11          2857 S L10
L12            11 S L11 AND CANCER
L13            10 S L12 NOT L7
L14             5 S L11 AND PROSTAT?
L15             4 S L14 NOT L12
L16             1 S L14 AND L12

=> s l6 and prostat?
         36032 PROSTAT?
L17              2 L6 AND PROSTAT?

=> s l17 not l7
L18              1 L17 NOT L7
```

Refine Search

Search Results -

Terms	Documents
succinimide.ti.	1255

Database: US Pre-Grant Publication Full-Text Database; US Patents Full-Text Database; US OCR Full-Text Database; EPO Abstracts Database; JPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L8 and (cancer or prostate)

Refine Search | Recall Text | Clear | Interrupt

Search History

DATE: Tuesday, December 30, 2003 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=AND			
L8	succinimide.ti.	1255	L8
L7	succinimide near fused	1	L7
L6	succinimide near fused	1	L6
L5	succinimide	19480	L5
DB=USPT; PLUR=YES; OP=AND			
L4	L3 and (cancer or prostate)	96	L4
L3	l1 and succinimide	386	L3
L2	L1 and prostate adj cancer	164	L2
L1	(514/408-448)![CCLS]	9275	L1

END OF SEARCH HISTORY

ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:675838 CAPLUS
DOCUMENT NUMBER: 137:216934
TITLE: Preparation of fused cyclic succinimide compounds and analogs thereof, as modulators of nuclear hormone receptor function
INVENTOR(S): Salvati, Mark E.; Attar, Ricardo M.; Gottardis, Marco M.; Balog, James A.; Pickering, Dacia A.; Martinez, Rogelio L.; Sun, Chongqing
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 331 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002067939	A1	20020906	WO 2002-US5302	20020220

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-271672P P 20010227
OTHER SOURCE(S): MARPAT 137:216934
GI



I



II

AB Title compds. I [G = (un)substituted cycloalkenyl, aryl or heterocyclo (mono or polycyclic); Z1 and Z2 independently = O, S, NH or substituted amine; L = bond, substituted alkyl chain, NH, substituted amine; A1 and A2 independently = CR1 or N when Y = J-J'-J'' where J = (CR1R1')n with n = 0-3, J' = bond, carbonyl, CR1R1', R2P:O, R2P:S, etc., and W = CR1R1'-CR1R1', CR3:CR3', (un)substituted cycloalkyl, etc.; or when Y is

absent A1 and A2 independently = CR1R1' or NR1; or when Y is absent A1, A2 and W together form -NR1-N:N-; Q1 and Q2 independently = H, (un)substituted alkyl, alkenyl, cycloalkyl, etc.; R1 and R1' independently = H, (un)substituted alkyl, alkenyl, cycloalkyl, cycloalkenyl, amino, halo, CN, etc.; R2 = (un)substituted alkyl, cycloalkyl, cycloalkenyl, heterocyclo, aryl, arylalkyl, etc.; R3 and R3' independently = H, (un)substituted alkyl, alkenyl, CN, halo, nitro, amino, etc.] are prepd. and methods of using such compds. in the treatment of nuclear hormone receptor-assocd. conditions, and pharmaceutical compns. contg. such compds are disclosed. Thus, II was prepd. by cyclocondensation of (3a.alpha.,4.beta.,8.beta.,8a.alpha.)-4,5,6,7,8,8a-hexahydro-4,8-etheno-1H-cyclohepta[c]furan-1,3(3aH)dione (prepn. given) with 3-(trifluoromethyl)aniline. Combinatorial methods of prepg. compds. of formula I are also provided. As modulators of nuclear hormone receptor function, the use of I as potential anticancer agents and for treatment of immune disorders is claimed (no data).

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:511091 CAPLUS
DN 139:85335
TI Preparation of fused heterocyclic compounds and analogs thereof as modulators of nuclear hormone receptor function
IN Salvati, Mark E.; Balog, James Aaron; Pickering, Dacia A.; Zhu, Hong
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 147 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003053358	A2	20030703	WO 2002-US40737	20021218
	WO 2003053358	A3	20031002		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003181728	A1	20030925	US 2002-322276	20021218
PRAI	US 2001-341962P	P	20011219		

OS MARPAT 139:85335

L13 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1999:421667 CAPLUS
DOCUMENT NUMBER: 131:58659
TITLE: Preparation of diaryl ureas as inhibitors of p38 kinase.
INVENTOR(S): Miller, Scott; Osterhout, Martin; Dumas, Jacques; Khire, Uday; Lowinger, Timothy Bruno; Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Gunn, David; Hatoum-Mokdad, Holia; Rodriguez, Mareli; Sibley, Robert; Wang, Ming
PATENT ASSIGNEE(S): Bayer Corporation, USA
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9932463	A1	19990701	WO 1998-US27265	19981222
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2315715	AA	19990701	CA 1998-2315715	19981222
AU 9919399	A1	19990712	AU 1999-19399	19981222
EP 1042305	A1	20001011	EP 1998-964221	19981222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001526276	T2	20011218	JP 2000-525400	19981222

PRIORITY APPLN. INFO.: US 1997-995749 A 19971222
WO 1998-US27265 W 19981222

OTHER SOURCE(S): MARPAT 131:58659

AB A method of treating a p-38 mediated disease other than **cancer** comprises administration of BNHCONHA [A = (substituted) Ph, pyridyl, 2-thienyl; B = (substituted) aryl, heteroaryl contg. .gtoreq.1 6-membered arom. structure contg. 0-4 N, O, or S atoms]. Thus, 5-tert-butyl-2-(3-tetrahydrofuranyloxy)aniline (prepn. given) and p-tolyl isocyanate were stirred 8 h in PhMe to give 75% N-(5-tert-butyl-2-(3-tetrahydrofuranyloxy)phenyl)-N'-(4-methylphenyl)urea. Title compds. inhibited p38 kinase with IC50 = 1-10 .mu.M.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1999:244628 CAPLUS
DOCUMENT NUMBER: 130:296612
TITLE: Preparation of amidocarboxylic acid derivatives as inhibitors of aldose reductase, 5-lipoxygenase, and lipid peroxide formation and as peroxisome proliferator-activated receptor (PPAR) activators
INVENTOR(S): Yanagisawa, Hiroaki; Sakurai, Mitsuya; Takamura, Makoto; Fujiwara, Toshihiko
PATENT ASSIGNEE(S): Sankyo Company, Ltd., Japan
SOURCE: PCT Int. Appl., 720 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9918066	A1	19990415	WO 1998-JP4396	19980930
W: AU, BR, CA, CN, CZ, HU, ID, IL, JP, KR, MX, NO, NZ, PL, RU, TR, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2305808	AA	19990415	CA 1998-2305808	19980930
AU 9892798	A1	19990427	AU 1998-92798	19980930
AU 738134	B2	20010906		
EP 1026149	A1	20000809	EP 1998-945527	19980930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9813019	A	20000905	BR 1998-13019	19980930
RU 2176999	C2	20011220	RU 2000-108440	19980930
US 6528525	B1	20030304	US 2000-540765	20000330
NO 2000001689	A	20000531	NO 2000-1689	20000331

PRIORITY APPLN. INFO.: JP 1997-269923 A 19971002
WO 1998-JP4396 W 19980930
OTHER SOURCE(S): MARPAT 130:296612
GI



I



II

AB Claimed and prepd. are amidocarboxylic acid derivs. (phenylalkanoic acids contg. arylcarboxamide derivs.) represented by general formula (I), pharmacol. acceptable salts thereof, or pharmacol. acceptable esters

thereof, [wherein R1 = H, linear or branched C1-6 alkyl, C7-12 aralkyl; R2 = linear or branched C1-6 alkylene; R3 = H, linear or branched alkyl C1-6 alkyl, C1-4 alkoxy, or C1-4 alkylthio, halo, NO2, di(linear or branched C1-4 alkyl)amino, (un)substituted C6-10 aryl, C7-12 aralkyl optionally having 1-5 substituents on the aryl, OH, linear or branched C1-5 aliph. acyl; R4 = H, linear or branched C1-6 alkyl; Z = linear or branched C1-6 alkylene; W = HO, linear or branched C1-6 alkyl, C1-4 alkoxy, or C1-4 alkylthio, (un)substituted C6-10 aryl, C6-10 aryloxy, C6-10 arylthio, C7-12 aralkyloxy, C7-12 aralkylthio, or C6-10 aryloxy-linear or branched C1-4 alkyl each optionally having 1-5 substituents on the aryl, 5- to 10-membered mono- or bicyclic heteroaryloxy contg. 1-4 heteroatoms selected from O, N, and S, etc.; X = C6-10 aryl optionally having 1-3 substituents, 5- to 10-membered mono- or bicyclic heteroaryl contg. 1-4 heteroatoms selected from O, N, and S; Y = single bond, O, S, (un)substituted NH]. Also claimed are blood sugar- and blood lipid-lowering agents, insulin resistance improver, antiinflammatory agents, immunomodulators, aldose reductase inhibitors, 5-lipoxygenase inhibitors, lipid peroxide formation inhibitors, PPAR activators, and anti-osteoporosis agents and therapeutic or prophylactic agents for diabetes, hyperlipemia, obesity, impaired glucose tolerance, insulin resistant non-impaired glucose tolerance, fatty liver, diabetes complications, gestational diabetes mellitus, polycystic ovary syndrome, osteoarthritis, rheumatoid arthritis, allergies, asthma, **cancers**, autoimmune diseases, pancreatitis, and cataract. Thus, N-deprotection of Et 2-ethoxy-3-[4-(2-phthalimidoethoxy)phenyl]propionate with hydrazine hydrate in MeOH at room temp. for 1.5 h followed by amidation with 4-pyridin-2-ylbenzoic acid using carbonyl diimidazole in CH2Cl2 at room temp. for 1. 5 h followed by sapon. with a mixt. of 1 N aq. NaOH and MeOH and acidification gave 3-[4-[2-(4-pyridin-2-ylbenzoylamino)ethoxy]phenyl]propionic acid deriv. (II.Na; R = H, R1 = Et) (III). III and (S)-II (R = H, R1 = 4-isopropoxyphenyl) in feed contg. 0.01% at .apprx.10 mg drug/kg/day for 3 days lowered blood sugar level by 43 and 73%, resp. A capsule, a tablet, and a granule formulation contg. III were prepd.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:922571 CAPLUS
DOCUMENT NUMBER: 139:375043
TITLE: Tandospirone and buspirone and their salts as analgesics for neurogenic pain
INVENTOR(S): Ono, Yukihiro; Soeda, Hiroko
PATENT ASSIGNEE(S): Sumitomo Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003335678	A2	20031125	JP 2002-143706	20020517

PRIORITY APPLN. INFO.: JP 2002-143706 20020517

AB Tandospirone and buspirone and their salts are claimed as analgesics for neurogenic pain, e.g. from surgery, diabetic neuropathy, herpes, sympathetic nerve atrophy, **cancer**, etc.